GRIFOLS S A/S (GRFS) Stock Rating Lowered by BidaskClub

GRIFOLS S A/S (NASDAQ:GRFS) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Wednesday.

GRFS has been the topic of a number of other research reports. Zacks Investment Research downgraded GRIFOLS S A/S from a “hold” rating to a “sell” rating in a research note on Tuesday, October 2nd. Morgan Stanley dropped their price target on GRIFOLS S A/S from $22.00 to $20.00 and set an “underweight” rating on the stock in a research note on Monday, October 1st. Berenberg Bank upgraded GRIFOLS S A/S from a “hold” rating to a “buy” rating in a research note on Thursday, October 11th. Finally, UBS Group downgraded GRIFOLS S A/S from a “neutral” rating to a “sell” rating in a research note on Wednesday, October 3rd. Four analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average price target of $21.50.

Shares of GRFS traded down $0.37 during mid-day trading on Wednesday, reaching $19.80. The company’s stock had a trading volume of 40,545 shares, compared to its average volume of 1,745,111. GRIFOLS S A/S has a 12-month low of $18.69 and a 12-month high of $25.18. The company has a market cap of $13.47 billion, a P/E ratio of 18.34, a PEG ratio of 1.38 and a beta of 1.21. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.12 and a current ratio of 2.90.

GRIFOLS S A/S (NASDAQ:GRFS) last released its quarterly earnings data on Friday, July 27th. The biotechnology company reported $0.34 EPS for the quarter, meeting analysts’ consensus estimates of $0.34. GRIFOLS S A/S had a return on equity of 18.32% and a net margin of 16.55%. The business had revenue of $1.31 billion for the quarter, compared to the consensus estimate of $1.35 billion. As a group, analysts predict that GRIFOLS S A/S will post 1.21 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. lifted its position in GRIFOLS S A/S by 14.9% during the 1st quarter. PNC Financial Services Group Inc. now owns 20,428 shares of the biotechnology company’s stock worth $433,000 after acquiring an additional 2,656 shares during the period. Blair William & Co. IL lifted its position in GRIFOLS S A/S by 9.9% during the 1st quarter. Blair William & Co. IL now owns 38,960 shares of the biotechnology company’s stock worth $826,000 after acquiring an additional 3,499 shares during the period. Verition Fund Management LLC lifted its position in GRIFOLS S A/S by 23.2% during the 2nd quarter. Verition Fund Management LLC now owns 18,818 shares of the biotechnology company’s stock worth $405,000 after acquiring an additional 3,539 shares during the period. BNP Paribas Arbitrage SA lifted its position in GRIFOLS S A/S by 14.3% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 34,055 shares of the biotechnology company’s stock worth $732,000 after acquiring an additional 4,255 shares during the period. Finally, Great West Life Assurance Co. Can lifted its position in GRIFOLS S A/S by 1.1% during the 2nd quarter. Great West Life Assurance Co. Can now owns 464,947 shares of the biotechnology company’s stock worth $9,990,000 after acquiring an additional 5,238 shares during the period. Hedge funds and other institutional investors own 21.05% of the company’s stock.

About GRIFOLS S A/S

Grifols, SA, a specialty pharmaceutical company, develops, manufactures, and distributes biological medicines on plasma derived proteins in the United States, Canada, Spain, rest of the European Union, and internationally. The company operates through five segments: Bioscience, Diagnostic, Hospital, Bio Supplies, and Others.

Featured Article: Stock Split

Analyst Recommendations for GRIFOLS S A/S (NASDAQ:GRFS)

Receive News & Ratings for GRIFOLS S A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GRIFOLS S A/S and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply